[ad_1]
Shanghai, January 28, 2022 /PRNewswire/ — HanBio Therapeutics (“HanBio”), a biotechnology company dedicated to the research and development of next-generation translational medicines, announced today that it has completed a $40 million Series A financing to advance the preclinical and clinical development of its portfolio of innovative antibodies and other biologics. This round of financing was jointly led by Aobo Pharmaceuticals and Hankang Capital, and followed by Yonghua Investment and Yikang Investment. Before the completion of this round of financing, HanBio was an early product development company incubated by Sunshine Guojian (Shanghai) Co., Ltd. (“Sunshine Guojian”). The company’s current pipeline includes three bispecific antibodies in the IND and pre-IND stages, as well as multiple early-stage antibody and other biologics products.
PhD. Zhenping ZhuThe founder, chairman and CEO of Hansheng Pharma said: “We are very grateful to investors such as Aobo Pharma and Hankang Capital for their recognition of Hansheng Pharma’s R&D capabilities, innovation pipeline and overall development strategy. This round of funds will be used for Preclinical research. Research and clinical trials of our multiple antibody and bispecific antibody products, as well as building efficient company management and R&D teams. We expect to submit IND applications to regulatory agencies in both countries China and America Launch of three innovative bispecific antibody products in 2022. On the research side, we will focus on exploring new therapeutic targets and…
The full story is available on Benzinga.com
[ad_2]
Source link
